Medivir is presenting an R&D update this afternoon on oral herpes project Lipsovir (ME 609) and the company's protease-based projects on Hepatitis C, osteoporosis and COPD (Chronic Obstructive Pulmonary Disease). A short summary will also be given on the status of the spin out process for the company's HIV projects, Medivir HIV Franchise AB.
Genetic Engineering News